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ABSTRACT: Anterior cruciate ligament (ACL) tears are among the most frequent knee injuries in sports medicine, with tear rates in
the US up to 250,000 per year. Many patients who suffer from ACL tears have persistent atrophy and weakness even after considerable
rehabilitation. Myostatin is a cytokine that directly induces muscle atrophy, and previous studies rodent models and patients have
demonstrated an upregulation of myostatin after ACL tear. Using a preclinical rat model, our objective was to determine if the use of a
bioneutralizing antibody against myostatin could prevent muscle atrophy and weakness after ACL tear. Rats underwent a surgically
induced ACL tear and were treated with either a bioneutralizing antibody against myostatin (10B3, GlaxoSmithKline) or a sham
antibody (E1-82.15, GlaxoSmithKline). Muscles were harvested at either 7 or 21 days after induction of a tear to measure changes in
contractile function, fiber size, and genes involved in muscle atrophy and hypertrophy. These time points were selected to evaluate
early and later changes in muscle structure and function. Compared to the sham antibody group, 7 days after ACL tear, myostatin
inhibition reduced the expression of proteolytic genes and induced the expression of hypertrophy genes. These early changes in gene
expression lead to a 22% increase in muscle fiber cross-sectional area and a 10% improvement in maximum isometric force production
that were observed 21 days after ACL tear. Overall, myostatin inhibition lead to several favorable, although modest, changes in
molecular biomarkers of muscle regeneration and reduced muscle atrophy and weakness following ACL tear.  2017 Orthopaedic
Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:2499–2505, 2017.
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With rates of up to 250,000 per year, anterior
cruciate ligament (ACL) ruptures are one of the most
common knee injuries to physically active individuals,
often interfering with their athletic career.1 Many
patients who suffer ACL tears develop persistent
atrophy and weakness of their quadriceps, even after
ACL reconstruction (ACL-R) and completion of a
rehabilitation program with good compliance. Several
studies demonstrate that quadriceps strength deficits
can exceed 30% at 6 months post ACL-R, and can
persist for longer periods of time.2,3 A reduction in
satellite cell abundance and whole muscle physiologi-
cal cross-sectional area is also observed in the quadri-
ceps after ACL tear.4 Other muscle groups in the hip,
thigh, and lower leg, such as the hip extensors, hip
adductors, knee flexors, and ankle dorsiflexors
and plantarflexors also experience varying degrees
of atrophy and weakness following ACL tear
(ACLT).2,5–7 Persistent weakness can lead to poor
physical performance, increase the risk for recurrent
injury, and alter knee kinematics in a way that
promotes early onset osteoarthritis.8–11 While the
majority of rehabilitation interventions targeted at
preventing muscle atrophy after ACL-R are focused
on neurogenic-mediated pathways of muscle inhibi-
tion,9 almost no studies have directly addressed the
cellular and molecular mechanisms of atrophy and
the loss of intrinsic force production in muscle fibers
themselves.
Myostatin (GDF-8) is a member of the transforming
growth factor-b (TGF-b) superfamily of cytokines and
functions to induce muscle fiber atrophy and weak-
ness.12 At the cellular level, myostatin induces muscle
atrophy by directly activating the ubiquitin-proteo-
some and autophagy pathways, and by blocking pro-
tein synthesis pathways activated by IGF-1
signaling.13–16 The mature myostatin protein sequence
is conserved across humans and rodents, and the
therapeutic inhibition of myostatin has been shown to
protect against atrophy, weakness, and fibrosis in
several different models of cancer cachexia and neuro-
muscular diseases.17,18 Patients with ACL tears have
up to a 50% increase in circulating levels of myosta-
tin,3 and data from a rat model of ACL tears demon-
strated a six-fold increase in myostatin expression in
quadriceps muscles.19 Since myostatin plays a central
role in directing muscle atrophy and is elevated in
quadriceps muscle after ACLT, it is a potentially
attractive therapeutic target in protecting against
weakness in patients with torn ACLs.
Given our limited ability to prevent muscle atrophy
in patients following ACLT and the high economic cost
and burdens associated with both the immediate and
long-term consequences of this atrophy, our objective
was to evaluate the ability of a bioneutralizing mono-
clonal antibody against myostatin (10B3, GlaxoS-
mithKline) to prevent muscle weakness after ACL
Conflicts of interest: Alan J Russell is an employee and stock-
holder of GlaxoSmithKline Pharmaceuticals, which holds patents
for the therapeutic anti-myostatin antibody used in this study
Grant sponsor: Orthopaedic Research and Education Foundation;
Grant sponsor: National Institute of Arthritis and Musculoskele-
tal and Skin Diseases; Grant number: F31-AR065931.
Correspondence to: Christopher L Mendias, (T: 734-764-3250;
F: 734-647-0003; E-mail: cmendias@umich.edu)
# 2017 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.
JOURNAL OF ORTHOPAEDIC RESEARCH NOVEMBER 2017 2499
tear. Using a preclinical rat model, we tested the
hypothesis that blocking myostatin activity after an
ACL tear will prevent atrophy of lower limb muscles
and also protect against the loss in muscle maximum
isometric force production.
METHODS
Animals and Surgical Procedure
This study was approved by the University of Michigan
IACUC, and followed PHS guidelines for the ethical treat-
ment of animals. Three month old male Fischer 344 rats
were obtained Charles River (Wilmington, MA) and housed
under specific pathogen free conditions. A total of 36 rats
were used in the study. Four rats served as non-operative
controls. The remaining 32 rats were randomly distributed
into four equal groups of eight, defined by their treatment
(sham antibody or anti-myostatin antibody) and time since
surgery (7 or 21 days), as described below. These time points
were selected based upon the work of Delfino and col-
leagues,3,16,19,20 our experience with other rat models of
muscle atrophy, and our clinical experience in treating
patients with ACL tears. The study was powered based on
maximum isometric force values of extensor digitorum
longus (EDL) muscles from a previous study.21 To detect a
30% difference between groups with a power of 0.80 required
a sample size of six per group. We included two additional
animals in each group. One rat was lost in each group except
for the 7 day myostatin antibody group, providing a N¼ 7 for
the 7 day sham antibody group, N¼ 8 for the 7 day myostatin
antibody group, N¼ 7 for the 21 day sham antibody group,
and N¼ 7 for the 21 day myostatin antibody group.
Surgical transection of the left hindlimb ACL was
performed, modified from Delfino and colleagues,19 to induce
mechanical instability and an acute arthropathy. Animals
were deeply anesthetized with 2% isoflurane and placed in a
supine position. The left knee was shaved and prepared with
ChloraPrep (CareFusion, El Paso, TX). A 1 cm midline skin
incision was made over the anterior left knee. The tibiofe-
moral joint was exposed using a lateral parapatellar
approach. With the knee in full flexion, the ACL and
intermeniscal ligament were identified and transected under
direct visualization, and instability was confirmed with a
positive anterior drawer test. The intermeniscal ligament
was transected to provide additional knee instability to
better model the human injury condition. The capsule was
closed with 4-0 Vicryl (Johnson & Johnson, New Brunswick,
NJ) sutures, the skin was closed using a subcutaneous
running suture of 4-0 Vicryl, and GLUture (Abbott Laborato-
ries, Abbott Park, IL) was applied over the incision. Subcuta-
neous buprenorphine at a dose of 0.05mg/kg was
administered for post-operative analgesia. Immediate
weightbearing and cage activity was allowed postoperatively
and rats were monitored for signs of distress or infection. All
rats were ambulatory and demonstrated signs of adequate
food and water intake.
At the time of surgery, rats received a single intraperito-
neal injection of a bioneutralizing murine anti-myostatin
monoclonal IgG antibody (10B3, GlaxoSmithKline, King of
Prussia, PA)22 or a sham murine anti-human papillomavirus
E1 helicase monoclonal IgG antibody (E1-82.15, GlaxoS-
mithKline)23 that does not bind to any endogenous rat
proteins. The dose of antibodies was 30mg/kg, with apparent
half lives greater than 7 days.22,23 This approach was
selected to block the acute effects of myostatin in the
immediate post-ACL tear period. Additional phamacokinetic
data about the MSTN mAb is available through US Patent
WO2010070094A1.
At either 7 or 21 days after tear, rats were anesthetized
with sodium pentobarbital. EDL muscles were removed to be
used for in vitro muscle contractility measurements. The EDL
was selected as a model of muscle function as several lower
limb muscles experience muscle atrophy after ACL tear, and
because of the frequent use of this muscle in studies of rodent
muscle function. The distal 1.5 cm of the vastus lateralis was
removed and fixed in 10% neutral buffered formalin (NBF) to
be used for histology. The distal 1.5 cm of the rectus femoris
muscle group was removed, finely minced and snap frozen at
80 ˚C for gene expression analysis. Following removal of
tissues, rats were euthanized by overdose of sodium pentobar-
bital followed by induction of bilateral pneumothorax.
EDL Contractility
Contractile properties of EDL muscles was performed as
previously described.21,24 The EDL was selected due to its
uniform architecture, its frequent use in rodent models of
muscle injury, and because patients with ACL tears have
ankle dorsiflexion strength deficits of 20% or more after
ACLT.6 A 4-0 silk suture was tied to the proximal and distal
tendons of intact EDL muscles, just distal to the aponeuro-
ses. Following suture placement, muscles were then removed
from the animal and immediately placed in a bath that
contained Krebs mammalian Ringer solution supplemented
with 11mM glucose and 0.3mM tubocurarine chloride. The
bath was maintained at 25 ˚C, and bubbled with a mixture of
95% O2 and 5% CO2 to maintain a stable pH of 7.4. The
distal tendon of the EDL was tied to a dual-mode servomo-
tor/force transducer (Aurora Scientific, Aurora, ON) and the
proximal tendon tied to a fixed hook. Using square wave
pulses delivered from platinum electrodes connected to a
stimulator (Aurora Scientific), muscles were stimulated to
contract. Custom designed software (LabVIEW, National
Instruments, Austin, TX) controlled pulse properties and
servomotor activity, and recorded data from the force trans-
ducer at 20 kHz. The voltage of pulses was serially increased,
and the muscle length was increased or decreased to provide
the length (Lo) that resulted in maximum twitch force.
Muscles were held at Lo and stimulated with pulse trains
of 300ms to generate isometric contractions. Stimulus
frequency was increased until maximum isometric force was
achieved. To calculate specific force, maximum isometric
force was divided by the physiological cross-sectional area
(PCSA), which was determined by dividing muscle mass by
the product of fiber length (Lf) and 1.056 g/cm
3, the density of
mammalian skeletal muscle. Following measurement of
contractile properties, muscles were fixed in 10% neutral
buffered formalin and prepared for histology.
Histology
Histology was performed as described.21,25 EDL and vastus
lateralis muscles were fixed in 10% NBF for 2 days, dehy-
drated in 70% ethanol and then embedded in paraffin.
Muscles were sectioned at the midbelly in a microtome at a
thickness of 10mm, rehydrated and stained with wheat germ
agglutin (WGA) lectin conjugated to AlexaFluor 488 (WGA-
AF488, Life Technologies, Carlsbad, CA) to identify extracellu-
lar matrix. Slides were imaged using a Zeiss Axiovert 200M
microscope (Carl Zeiss, Thornwood, NY), and ImageJ software
(NIH, Bethesda, MD) was used to perform quantitative fiber
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cross-sectional area (CSA) measurements. All fibers in cross-
section were counted by two independent assessors who were
blinded to the study treatment groups.
Gene Expression
Gene expression was performed as described.21,25 Total RNA
was isolated from homogenized rectus femoris muscles using a
miRNeasy kit (Qiagen, Valencia, CA). After treatment with
DNase I (Qiagen), RNA was reverse transcribed into cDNA
with iScript supermix (Bio-Rad, Hercules, CA), and quantita-
tive PCR (qPCR) was conducted in a CFX96 real time thermal
cycler using iTaq SYBR green supermix reagents (Bio-Rad).
The 2DDCt technique was used to normalize the expression of
RNA transcripts to the stable housekeeping gene b-actin, and
each of the treatment groups was further normalized to
control, non-operated muscles. A listing of RNA transcripts
and primer sequences is provided in Supplementary Table S1.
Statistics.
Data are presented as meanSD. Differences between
treatment groups were tested with a two-way ANOVA
(a¼ 0.05) followed by Fisher’s LSD post-hoc sorting in
GraphPad Prism 6.0 (La Jolla, CA).
RESULTS
No difference in body mass was observed between the
sham mAb or MSTN mAb group at either 7 days
(2547 g for sham mAb, 261 9 g for MSTN mAb) or
21 days (30012 g for sham mAb, 30411 g for
MSTN mAb). For EDL muscle fiber cross-sectional
area (CSA) (Fig. 1A), no differences were observed
between the 7 day groups. The 21 day sham mAb
group was approximately 40% greater than the 7 day
groups, but the 21 day MSTN mAb group had
approximately 54% greater CSA values than the 7 day
groups, and was also 22% greater than the 21 day
sham mAb group. Similar trends were observed for
vastus lateralis muscles (Fig. 1B).
There was a time-dependent effect on EDL muscle
mass and PCSA, with both groups at 21 days having
an approximately 15% increase in mass and a 13%
increase in PCSA compared to 7 day groups
(Fig. 2A and B). For maximum isometric force
(Fig. 2C), the 21 day MSTN mAb group had the
highest values, which were approximately 21% greater
than both 7 day treatment groups and 10% greater
than the 21 day sham mAb group. No differences in
specific force were observed between groups, suggest-
ing no changes in the overall density of myofibrils in
muscle fibers (Fig. 2D).
We next measured the expression of several genes
involved in muscle atrophy and hypertrophy (Fig. 3).
Nearly all genes at all time points were elevated
compared to control, uninjured muscles. For the ubiq-
uitin ligases atrogin-1, MuRF-1, and MUSA-1, which
are important rate limiting steps in muscle protein
degradation, myostatin mAb treatment resulted in a
downregulation in the expression of these genes at
7 days compared to the sham mAb group, although no
differences between groups were present at 21 days.
Similar observations were made for Beclin-1, which
plays a central role in autophagy. IGF-1Ea and IGF1-
Eb which play important roles in activating signaling
cascades that promote muscle protein synthesis, as well
as the 18S ribosomal rRNA subunit which directly
translates mRNAs into proteins, were induced by
treatment with myostatin mAb at 7 days.
Finally we measured the expression of genes in-
volved in extracellular matrix (ECM) synthesis and
fibrosis (Fig. 4). Similar to transcripts involved in
muscle atrophy and hypertrophy, nearly all measured
genes were upregulated compared to control, unin-
jured muscles. Type I and III collagen, which are the
major ECM proteins in skeletal muscle, were both
downregulated by myostatin mAb treatment at 7 days
compared to the sham mAb group, as was FSP-1,
which is a marker of muscle fibroblasts. No difference
was observed for the major muscle gelatinase MMP-2
between groups at different time points, but myostatin
mAb treatment decreased the expression of the major
muscle collagenase MMP-8 at 7 days. Similar observa-
tions were made for inhibitors of MMPs, TIMP-1, and
Figure 1. Histology. Muscle fiber cross-sectional areas of (A) Extensor digitorum longus and (B) Vastus lateralis muscles from sham
mAb and anti-myostatin mAb treated animals 7 or 21 days after inducing ACL tear. Values are meanSD, N7 for each group.
Dashed line indicates mean values from control, uninjured animals. Differences tested with a two-way ANOVA (a¼0.05) followed by
Fisher’s LSD post-hoc sorting. Letters above bar graphs indicate post-hoc sorting differences.
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TIMP-2, although myostatin inhibition at 21 days also
resulted in a downregulation in the expression of these
genes compared to the 21 day sham group.
DISCUSSION
Many patients with ACL tears have persistent muscle
atrophy and weakness of 30% or greater despite
compliance with intense postoperative rehabilitation
programs.2,3 Myostatin is a potent muscle atrophy-
inducing cytokine that is elevated after ACL tear.3,19
We hypothesized that blocking myostatin activity with
a bioneutralizing monoclonal antibody would prevent
the atrophy of lower limb muscles and also protect
against the loss in muscle maximum isometric force
Figure 2. Extensor digitorum longus (EDL) muscle mass and in vitro contractility measurements. (A) Muscle mass, (B) physiological
cross-sectional area (PCSA), (C) Maximum isometric force, (D) Specific force (maximum isometric force normalized to PCSA) of EDL
muscles from sham mAb and anti-myostatin mAb treated animals 7 or 21 days after inducing ACL tear. Values are meanSD, N7
for each group. Dashed line indicates mean values from control, uninjured animals. Differences tested with a two-way ANOVA
(a¼ 0.05) followed by Fisher’s LSD post-hoc sorting. Letters above bar graphs indicate post-hoc sorting differences.
Figure 3. Atrophy and hypertrophy-related gene expression. Gene expression, measured by quantitative PCR, from rectus femoris
muscles. Target genes were normalized to the expression of the stable housekeeping gene b-actin, and then further normalized to the
relative expression of that gene in control muscle from an uninjured knee. Any expression value greater than 1 indicates an
upregulation compared to control muscle, and values less than 1 indicates a downregulation compared to control muscle. Values are
meanSD, N 7 for each group. Differences tested with a two-way ANOVA (a¼0.05) followed by Fisher’s LSD post-hoc sorting.
Letters above bar graphs indicate post-hoc sorting differences.
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production. The outcomes from the current study indi-
cate that myostatin inhibition was able to reduce the
expression of proteolytic genes, leading to improve-
ments in muscle fiber size and strength. Reductions in
the expression of genes involved in ECM accumulation
and fibrosis were also observed. The combined results
of this preclinical study indicate that blocking myosta-
tin is able to protect against some of the muscle atrophy
and weakness that occur following an ACL tear.
Myostatin is widely regarded as a key regulator of
muscle protein degradation. Inactive myostatin is
sequestered to its inhibitory propeptide and other
binding proteins in the ECM of muscle.15 Following
injury and immobilization, active myostatin can be
released from the matrix by proteolytic degradation of
the propeptide and binding proteins by various pro-
teases.15 Once activated, myostatin can bind to the
ACVR2A and ACVR2B receptors, as well as the ALK4
and ALK5, to initiate activation of the Smad2/3 and
p38 MAPK pathways in skeletal muscle cells.26 Among
the downstream targets of these pathways are the
E3-ubiquitin ligases atrogin-1 and MuRF-1 which
direct proteins for breakdown in the 26S proteasome.12
Although the molecular mechanisms are not fully
understood, myostatin also appears to be able to
activate autophagy in muscle cells, which is a parallel
protein breakdown pathway to the ubiquitin protea-
some system.16,27 IGF-1 is one of the major muscle
growth factors and works primarily by increasing
muscle protein synthesis, and in addition to turning
on protein degradation, myostatin can also block
muscle growth by inhibit IGF-1 signaling.13
During physiological growth, such as muscle hyper-
trophy that occurs as a result of resistance exercise
training, myostatin plays an important role in turning
on proteolytic pathways to breakdown proteins that are
damaged during eccentric contractions.15 However in
severe muscle or joint injuries, or following immobiliza-
tion, myostatin levels are dramatically elevated which
leads to profound muscle atrophy and persistent weak-
ness.3,16,19,20 In the current study, 7 days after ACL
tear the inhibition of myostatin lead to a decrease in
atrogin-1, MuRF-1, and the related ubiquitin ligase
MUSA-1, as well as Beclin-1 which is a key factor in
the initiation of phagophore nucleation in autophagy.28
Myostatin inhibition also increased the expression of
the two IGF-1 isoforms as well as 18S rRNA, which is a
core subunit of ribosome organelles that directly syn-
thesize proteins in cells. However, by 21 days there
were no differences between myostatin antibody and
sham antibody treated groups in molecular regulators
of muscle size. Interestingly, while dramatic effects
were observed 7 days after tear at the molecular level,
no functional changes in muscle size or contractility
occurred at the same time point, but by 21 days an
increase in muscle fiber size and maximum isometric
force production were observed in the myostatin inhibi-
tor treatment group. These results suggest that the
therapeutic inhibition of myostatin in the acute post-
ACL tear injury phase leads to early, modest positive
changes in the expression of genes that regulate muscle
atrophy and growth, which then lead to more rapid
recovery of muscle fiber size and force production.
Muscle ECM accumulation and fibrosis can occur
after injury, joint trauma and in chronic degenerative
myopathies.29 In general, excessive ECM accumulation
can interfere with lateral force transmission between
muscle fibers, leading to increased susceptibility to
eccentric injuries.30 While less is known about muscle
fibrosis and ECM accumulation in patients with ACL
tears, collagen accumulation was reported in the
quadriceps muscles of rats with ACL tears.31 In
addition to inducing protein degradation, myostatin
signaling can also induce the expression of type I
Figure 4. Extracellular matrix-related gene expression. Gene expression, measured by quantitative PCR, from rectus femoris
muscles. Target genes were normalized to the expression of the stable housekeeping gene b-actin, and then further normalized to the
relative expression of that gene in control muscle from an uninjured knee. Any expression value greater than 1 indicates an
upregulation compared to control muscle, and values less than 1 indicates a downregulation compared to control muscle. Values are
meanSD, N 7 for each group. Differences tested with a two-way ANOVA (a¼0.05) followed by Fisher’s LSD post-hoc sorting.
Letters above bar graphs indicate post-hoc sorting differences.
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collagen and several genes that regulate ECM struc-
ture and function.21,32,33 In the current study, thera-
peutic inhibition of myostatin lead to several
encouraging changes in the expression of ECM genes,
including a reduction in type I and III collagen and
FSP-1, which is a marker of muscle fibroblasts. No
difference between groups at each time point was
observed for MMP-2, and modest reductions in the
major muscle collagenase MMP-8, as well as a down-
regulation in the MMP inhibitors TIMP-1 and -2 were
present. Although the extent of fibrosis and its contri-
bution to contractile dysfunction in patients with ACL
tears has not been well documented, if the same effects
are observed in other muscle injuries and disorders,
the changes in collagen, MMP and TIMP genes
observed in this study likely suggest an overall favor-
able effect of myostatin inhibition on muscle ECM
composition after ACL tear.
There are several limitations to this study. Rats are
frequently used as a preclinical model to study ACL
tears, but the open surgical method of ACL tear used in
this study differs substantially from the mechanical
disruption of the ligament that occurs with closed
cutting or pivoting knee injury in patients. We measured
the expression of several genes, and while we do not
anticipate substantial posttranslational regulation of
these transcripts, it is possible that changes in RNA
levels would not predict subsequent changes in protein
abundance. Three month old rats were selected for this
study, and modest increases in body mass would be
expected in these rats at this age. Whole animal
functional performance measures like stability and
balance were not performed. We evaluated the contrac-
tility of the EDL as the simple architecture of the muscle
provides a convenient way to measure force production
in vitro, and because this is one of the most common
muscles used to asses function in studies of muscle
atrophy in rodents, but did not measure the function of
the quadriceps group which tend to be most severely
affected muscle group after ACLT. Improvements in
muscle size and function were seen in both sham and
MSTN mAb groups over time. However, this is similar
to what is frequently observed in patients, who are
typically non-ambulatory immediately after ACLT. By
several weeks after the injury they are able to walk and
even run, albeit with an unstable knee, and objective
deficits in muscle strength in the affected limb.2,3 This is
also likely why numerous atrophy and fibrosis associated
genes were downregulated in both groups at 21 days
compared to 7 days. A single dose of myostatin inhibitor
was used and the changes were evaluated at only two
time points. Performing multiple doses over a longer
period of time would provide additional insight into the
mechanism of action of the drug. The antibodies used in
this study were generated in mouse, and it is likely that
the rats in this study generated antibodies against these
mouse proteins. This phenomenon is frequently encoun-
tered in testing antibodies that have potential pharma-
ceutical use in preclinical models.34 While this is a
known limitation and not unique to this study, it
generally takes some time for an organism to generate
sufficient antibodies to decrease the efficacy of therapeu-
tic antibody being tested, in some cases up to two
weeks.34 Therefore it is likely that the ability of the
antibody to block myostatin in the acute post-tear phase
was preserved. To further ensure this was the case, we
administered a relatively high dose of the antibody
(30mg/kg). Despite these limitations, this study provided
important insight into the biology of muscle changes
after ACLT and also identified a potentially promising
pharmacological therapy for the treatment of muscle
atrophy in patients with an ACLT.
Muscle atrophy and persistent weakness commonly
occur after ACLT, and this atrophy limits the return to
play of patients and may contribute to the development
of early OA. In the current study, inhibition of myosta-
tin immediately following ACLT lead to modest
improvements in markers of muscle growth, and func-
tional changes in muscle fiber size and force production.
However, there are some concerns within the sports
medicine community as to the potential use of myosta-
tin inhibitors as doping agents. While we report
functional improvements in muscle size and contractil-
ity in this paper, there was no effect of myostatin
inhibition on muscle specific force values. This parame-
ter, which normalizes muscle force by cross-sectional
area, can be increased through the use of anabolic
agents,35 but studies in animals have shown that
inhibiting myostatin in otherwise healthy muscle is
unable to increase muscle fiber specific force produc-
tion.14,21 These papers, along with the results from the
current study, suggest that myostatin inhibition is able
to preserve muscle size and strength, to some extent,
after injury and disease by blocking protein catabolism
and not necessarily by increasing protein anabolism.
While further research is necessary, given the encour-
aging results from this preclinical study, the targeted
inhibition of myostatin along with accelerated rehabili-
tation programs may be able to improve the long-term
functional outcomes of patients with ACL tears.
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